Pooled Analysis of the Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients With Ovarian Cancer by Fehm, Tanja et al.
Pooled Analysis of the Prognostic Relevance of
Disseminated Tumor Cells in the Bone Marrow of Patients
With Ovarian Cancer
Tanja Fehm, MD, PhD,* Malgorzata Banys, MD,Þþ Brigitte Rack, MD, PhD,§
Wolfgang Janni, MD, PhD,|| Christian Marth, MD, PhD,¶ Christina Blassl,Þ Andreas Hartkopf, MD,Þ
Claes Trope, MD, PhD,# Rainer Kimmig, MD, PhD,** Natalia Krawczyk, MD,*
Diethelm Wallwiener, MD, PhD,Þ Pauline Wimberger, MD, PhD,ÞÞ and Sabine Kasimir-Bauer, PhD**
Objective: Detection of disseminated tumor cells (DTCs) in the bone marrow (BM) of
patients with breast cancer is associated with poor outcomes. Recent studies demonstrated
thatDTCsmay serve as aprognostic factor inovariancancer.Theaimof this 3-center studywas to
evaluate the impact of BM status on survival in a large cohort of patients with ovarian cancer.
Materials and Methods: Four hundred ninety-five patients with primary ovarian can-
cer were included in this 3-center prospective study. Bone marrow aspirates were collected
intraoperatively from the iliac crest. Disseminated tumor cells were identified by antibody
staining and by cytomorphology. Clinical outcome was correlated with the presence of DTCs.
Results: Disseminated tumor cells were detected in 27% of all BM aspirates. The number
of cytokeratin-positive cells ranged from 1 to 42 per 2  106 mononuclear cells. Dis-
seminated tumor cell status did correlate with histologic subtype but not with any of the
other established clinicopathologic factors. The overall survival was significantly shorter
among DTC-positive patients compared to DTC-negative patients (51 months; 95% con-
fidence interval, 37Y65 months vs 33 months; 95% confidence interval, 23Y43 months; P =
0.023). In the multivariate analysis, BM status, International Federation of Gynecology and
Obstetrics stage, nodal status, resection status, and age were independent predictors of
reduced overall survival, whereas only BM status, International Federation of Gynecology
and Obstetrics stage, and resection status independently predicted progression-free survival.
Conclusions: Tumor cell dissemination into the BM is a common phenomenon in ovarian
cancer. Disseminated tumor cell detection has the potential to become an important bio-
marker for prognostication and disease monitoring in patients with ovarian cancer.
Key Words: Ovarian cancer, Disseminated tumor cells, Overall survival, Progression-free
survival, Bone marrow
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Ovarian cancer is currently the fifth leading cause of cancer
death of women in Europe and the United States.1 The
prognosis of patients with ovarian cancer is limited owing to
the lack of early symptoms and a high rate of recurrence. The
disease is diagnosed in most patients at an advanced stage,
and although the initial response to chemotherapy is generally
good, a significant proportion of patients will have a relapse
despite optimal treatment based on current guidelines.2 The
identification of new biomarkers, reflecting current disease
status and tumor activity, could optimize prediction and
monitoring of oncologic treatment and provide insights
into the biology of ovarian cancer. In this regard, recent
studies have increasingly focused on disseminated tumor
cells (DTCs) in the bone marrow (BM).
The presence of DTCs is a common phenomenon in
solid tumors of epithelial origin. For breast cancer, DTC
detection has been demonstrated to be a strong independent
prognostic factor (level I evidence).3 Available data support
the notion that hematogenous tumor cell dissemination may
be clinically relevant in ovarian cancer as well.4Y8 Detection
rates of DTC, as a surrogate parameter for occult hematog-
enous spread, vary between 30% and 50% of patients with
primary ovarian cancer. Interestingly, ovarian metastases to
the bone are only rarely observed.5,9,10 Possibly, BM acts as
a secondary ‘‘homing site’’ in these patients where tumor
cells are able to persist and may subsequently cause a relapse.
The aim of the present 3-center study was to prospec-
tively evaluate the impact of BM status on clinical outcome in
a group of 495 patients treated for ovarian cancer at 3 com-
prehensive cancer centers (University Hospital Tuebingen,
Germany;UniversityHospital Essen, Germany; andUniversity
Hospital Munich, Germany).
MATERIALS AND METHODS
This 3-center analysis was performed at the Depart-
ment of Obstetrics and Gynecology, University Hospital
Tuebingen, Germany; the Department of Gynecology and
Obstetrics, University Hospital Essen, Germany; and the
Department of Gynecology and Obstetrics, University Hos-
pital Munich, Germany. A total of 495 patients with ovarian
cancer patients (International Federation of Gynecology and
Obstetrics [FIGO] stages IYIV) treated between January 1994
to November 2010 in these centers were included in the
analyses (Tuebingen, 229 patients [46%]; Essen, 148 patients
[30%]; and Munich, 118 patients [24%]). The patients’
characteristics at the time of diagnosis are shown in Table 1.
All specimens were obtained after written informed consent.
Tissue sampling and analysis of datawere approved by the local
ethic committee (114/2006A, 05-2870). Treatment of ovarian
cancer and follow-up examinations were performed according
to current treatment guidelines. Relapse was confirmed by
physical examination, computed tomographic scan, x-ray, ul-
trasound, tumor marker, and/or relaparotomy depending on
localization of recurrence.
Preparation of Slides
Detection of DTCs was performed as described in detail
previously for all 3 centers.4 Ten to 20-mL BM was aspirated
intraoperatively from the iliac crest of both sides into syringes
containing heparin anticoagulant under general anesthesia
using the Jamshidi technique. Bone marrow samples were
processed within 24 hours. Tumor cell isolation and detection
were performed based on the recommendations for standard-
ized tumor cell detection.11 Briefly, samples were separated
by density centrifugation using Ficoll (density, 1077 g/mL;
Biochrom, Germany). Mononuclear cells (MNCs) were col-
lected from the interphase layer, spun down onto a glass slide
(106 MNCs per spot; Hettich cytocentrifuge, Tuttlingen,
Germany) and air-dried overnight at room temperature.
Staining of Slides and DTC Identification
For detection of cytokeratin (CK)-positive tumor
cells, slides were fixed in 4% neutral buffered formalin for
10 minutes and rinsed in phosphate-buffered saline. Auto-
matic immunostaining was performed on the DakoAutostainer
TABLE 1. Incidence of DTC in patients with ovarian






Total 495 134 (27)
FIGO stage 0.459
I 87 27 (31)
II 33 12 (36)
IIIYIV 342 93 (27)
Nodal status 0.061
N0 211 70 (33)
N1 209 52 (25)
Grading 0.107
G1 41 6 (15)
G2 184 57 (31)
G3 223 65 (29)
Histologic type 0.026
Serous high-grade 313 88 (28)
Serous low-grade 30 2 (7)
Mucinous 19 9 (47)
Endometrioid 29 8 (28)
Clear cell 10 5 (50)
Other 11 3 (27)
Resection status 0.632
No remaining tumor 239 73 (30)
Tumor rest 190 54 (28)
Age, yrs 0.116
0Y29 12 2 (17)
30Y49 108 27 (25)
50Y69 273 68 (25)
70Y89 102 37 (36)
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using the monoclonal mouse A45-B/B3 antibody (Micromet,
Munich, Germany) and the DAKO-APAAP detection kit
(DakoCytomation, Glostrup, Denmark) according to the manu-
facturer’s instructions. The A45-B/B3 antibody is directed
against a common epitope of CK polypeptides, including the
CK heterodimers 8/18 and 8/19. The A45-B/B3 antibody is
the most extensively studied antibody for DTC detection in
ovarian cancer to date.4,5,9,12 Reproducibility of DTC detection
by A45-B/B3 antibody has been tested by using ovarian cancer
cell line SKOV3.12 In our analysis, for reasons of feasibility
in the clinical laboratory routine the malignant breast cancer
cell lineMCF-7was used as a positive control. For each patient,
2  106 cells were analyzed on 2 slides. All slides were eval-
uated by 2 independent cytologists. In case nonconcordant
results were obtained, the slides were evaluated by a third in-
vestigator to obtain consensus. Identification of tumor cells
was performed according to the ISHAGE evaluation criteria
and the DTC consensus statements.
Statistical Analysis
The W2 test and the Fisher exact test were used to evaluate
the relationship between circulating tumor cells (CTCs) and
clinicopathological factors. For the survival analysis, we con-
sidered in separate analyses the following primary end points:
(1) death and (2) relapse, defined as distant or local disease
recurrence, or both. Survival intervals were measured from
the time of BM aspiration to the time of death or of the first
clinical, histological, or radiographic diagnosis of relapse. We
constructed Kaplan-Meier curves and used the log-rank test to
assess the univariate significance of the parameters. The effects
of multiple variables on survival were evaluated by a Cox
proportional-hazards regression model. All reported P values
are 2-sided. The initial model included BM status, age at di-
agnosis, FIGOstage, nodal status, resection status, and grading.
Subjects with missing values were excluded from model-
ing. Statistical analysis was performed by SPSS version 17.0




Bone marrow aspirates were obtained intraoperatively
from 495 patients with primary ovarian cancer. Most (74%)
of the patients were at FIGO stages III to IV, 19% at FIGO stage
I, and 7% at FIGO stage II. The mean age was 58 years (range,
18Y88 years). Disseminated tumor cells were detected in
134 (27%) of 495 BM aspirates. The number of CK-positive
cells ranged from 1 to 42 per 2  106 mononuclear cells.
Bone marrow status did not correlate with age (P = 0.116),
FIGO stage (P = 0.459), lymph node status (P = 0.061), his-
topathologic grading (P= 0.107), or resection status (P= 0.632;
Table 1). The lowest prevalence of positive BM status was
observed in patients with low-grade serous cancer (7%),
whereas 28% of patients with high-grade serous carcinoma
presented with DTC (P = 0.011). The prevalence of DTC
presence in other histologic subtypes is presented in Table 1.
BM Status and Progression-Free Survival
Patients were not considered for survival analysis if the
follow-up period was less than 4 months. Thus, follow-up data
were available in 456 cases. Only these patients were included








Total 196 (43) 198 (43)
DTC status
DTC positive 125 64 (51) 60 (48)
DTC negative 331 132 (40) 138 (42)
Relapse is defined as either local recurrence or distant metastasis
(median follow-up: 46 months).
FIGURE 1. Kaplan-Meier survival analysis depending on BM status, P values calculated by the log-rank test
(a, OS; b, PFS).
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in the survival analysis. Median follow-up was 46 months
(range, 4Y104 months). Data on clinical outcome are summa-
rized in Table 2. One hundred ninety-eight patients (43%) had
recurrence during follow-up. Relapse was diagnosed in 48% of
DTC-positive and 42% of DTC-negative patients (P = 0.225).
Median progression-free survival (PFS) was shorter in patients
with DTC in the BM (29 months; 95% CI, 22Y36 months vs
24 months; 95% CI, 18Y30 months; P = 0.164, determined by
log-rank test; Fig. 1). In the multivariate regression analysis,
BM status (P = 0.030), FIGO stage (P G 0.001), and resection
status (P = 0.003) were the only independent predictors of
PFS (Table 3).
BM Status and Overall Survival
One hundred ninety-six patients (43%) died during
follow-up. Patients with DTCwere more likely to die than BM-
negative patients (51% vs 40%; P = 0.029). The median overall
survival (OS) was significantly shorter among DTC-positive
patients compared with DTC-negative patients (51 months;
95% CI, 37Y65 months vs 33 months; 95% CI, 23Y43 months;
P = 0.023, determined by log-rank test). Survival curves are
presented in Figure 1. Multivariate Cox regression model con-
firmed BM status as a strong independent predictor of shorter
OS (P = 0.001). Age at diagnosis (P = 0.004), FIGO stage (P G
0.001), nodal status (P = 0.022), and resection status (PG 0.001),
but not the grading, also predicted reducedOS in themultivariate
analysis (Table 3). In the subgroup analysis, BM status was a
strong predictor of OS in patients with high-grade serous car-
cinoma (295 patients; P = 0.001; Fig. 2). The subgroup analysis
was not performed for other histologic types owing to small
sample sizes. The prognostic effect of BM status was assessed
within FIGO stages; for FIGO stage III to stage IV tumors
(n = 299), a significant association with OS was confirmed
(P = 0.001; Fig. 3). No significant correlation with OS was
observed in FIGO I (n = 84) and FIGO II (n = 31) tumors
when analyzed separately.
DISCUSSION
This is the largest pooled analysis so far on the prognostic
relevance of DTC in primary ovarian cancer. A total of 495
patients were included in this prospective 3-center analysis.
Disseminated tumor cells, as a surrogate parameter for minimal
residual disease, could be detected in 27% of the patients,
irrespective of the stage of the disease.
Other studies reported DTC incidence ranging from 20%
to 60% in primary ovarian cancer, depending on the method-
ology and patients’ collective.4Y6,8,13Y16 Interestingly, ovarian
malignancies rarely cause bonemetastases.10 This suggests that
BMserves in these patients rather as a temporary ‘‘homing site’’
for isolated tumor cells, from where they are able to migrate
and subsequently cause metastasis or locoregional recur-
rence. Because hematogenous dissemination of isolated tu-
mor cells may already be observed in FIGO stage I, it may
be hypothesized that contrary to the assumed natural history
of ovarian cancer, single tumor cells acquire the potential to











0.030 1.490 1.038 2.137
FIGO stage
(IIIYIV vs II vs I)
G0.001 2.966 1.992 4.416
Nodal status (positive
vs negative)
0.386 0.855 0.600 1.218
Grading (G3 vs
G2 vs G1)
0.844 1.030 0.765 1.388
Resection status
(R2 vs R1 vs R0)
0.003 1.396 1.122 1.738
Age (70Y89 vs 50Y69
vs 30Y49 vs 0Y29
0.553 0.930 0.731 1.183
OS
DTC status (positive vs
negative)
0.001 1.892 1.321 2.712
FIGO stage (stage 3Y4
vs 2 vs 1)
G0.001 4.055 2.103 7.819
Nodal status (positive
vs negative)
0.022 1.585 1.068 2.354
Grading
(G3 vs G2 vs G1)
0.765 1.049 0.767 1.434
Resection status
(R2 vs R1 vs R0)
G0.001 1.741 1.401 2.163
Age (70Y89 vs 50Y69
vs 30Y49 vs 0Y29)
0.004 1.486 1.134 1.948
BM status and established prognostic factors, such as FIGO stage,
nodal status, resection status, age at diagnosis, and grading were in-
cluded in this statistic model. a) progression-free survival; b) overall
survival.
FIGURE 2. Subgroup analysis: high-grade serous
carcinoma (n = 295); Kaplan-Meier OS analysis.
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disseminate to extraperitoneal sites very early in the process of
the disease.5 Because DTCs may spread by means of the blood
stream, we cannot exclude that those might also be able to
repopulate the peritoneal cavity, an environment that easily
supports ovarian cancer growth.
Influence of DTC Detection on
Clinical Outcome
For ovarian cancer, data on the prognostic value of DTCs
are so far limited (Table 4). In the present study, presence of
DTCs predicted significantly shortened OS (P = 0.001 in the
multivariate survival analysis). This is in accordance with
several smaller studies. Braun et al5 demonstrated impaired
prognosis with regard to distant disease-free survival (DFS) in
BM-positive patients at the time of diagnosis; in a subset of
64 optimally debulked patients, DTC presence remained a
strong prognostic factor (P = 0.002), which highlights the role
ofDTCdetection especially in patientswho received successful
surgical cytoreduction. We previously reported a significant
correlation of positive BM status with reduced DFS in a group
of 112 patients with FIGO stage I to stage III ovarian cancer.4
Interestingly, in some studies, the presence of isolated tumor
cells in secondary sites such as BM and blood was also asso-
ciatedwith higher risk for local recurrence aswell.4,7 Therefore,
it might be speculated that hematogenous tumor cell dissemi-
nationmay serve as an indicator of amore aggressive phenotype
of the primary disease that is likely to cause local relapse. In
contrast, other authors reported no significant correlation be-
tween DTC detection and clinical outcome in ovarian can-
cer.13,17 This discrepancy might be due to differences in study
protocols, for example, time point of BM sample collection
(preoperative vs postoperative aspiration). Hypothetically, a
transient increase in cancer cell dissemination from the primary
tumor due to intraoperative manipulation could contribute to
false-positive results and therefore affect further analysis.18
Interestingly, in the current analysis, BM status did not
influence PFS. This may be due to inconsistent relapse di-
agnosis. Most patients were treated within a clinical trial;
FIGURE 3. Subgroup analysis: patients with FIGO stages
III to IV (n = 299); Kaplan-Meier OS analysis.
TABLE 4. Prognostic relevance of DTC and CTC in ovarian cancer







Our study 456 DTC (ICC) 46 27 OS, PFS*
Banys et al4 112 DTC (ICC) 12 25 DFS
Braun et al5 108 DTC (ICC) 45 30 DFS
Aktas et al6 95 DTC (ICC) 28 35 ns
Schindlbeck et al8 90 DTC (ICC) 28 23 DDFS
Marth et al13 73 DTC (immunobeads) 25 21 ns
Wimberger et al14 62 DTC (ICC) 18 54 DFS†
Poveda et al7 216 CTC (ICC: CellSearch)‡ 14§ PFS, OS
Marth et al13 90 CTC (immunomagnetic beads) 25 12 ns
Aktas et al6 86 CTC (multiplex-RT-PCR: AdnaTest) 28 19 OS||
Heubner et al16 68 Circulating 20S-proteasomes 19 V OS
Fan et al15 66 CTC (immunofluorescence and cell
invasion assay)
18 61 DFS
Wimberger et al14 62 Circulating nucleosomes, DNA,
protease and caspase activity
18 V DFS, OS
*Determined by multivariate Cox regression analysis.
†Disseminated tumor cells detected after chemotherapy.
‡Relapsed ovarian cancer.
§Two or more CTCs.
||Both before and after chemotherapy.
DDFS, Distant disease-free survival; ICC, immunocytochemistry; ns, not significant; RT-PCR, reverse-transcriptase polymerase chain reaction
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these patients received intensified follow-up with computed
tomographic scans at regular intervals. In the group of patients
treated outside clinical trials, follow-up care was carried out
according to national guidelines and was based on clinical
examination and patients’ symptoms. Possibly, relapse was
diagnosed later in the group treated outside clinical trials.
Disease Monitoring
Beyond the prognostic value of DTC detection, moni-
toring of minimal residual disease during and after treatment
offers the opportunity to assess the residual risk of relapse. The
presence of DTCs and/or CTCs may indicate persistent occult
tumor load after treatment and thus an insufficient therapy
response. Wimberger et al12 assessed changes in DTC levels
before and after first-line chemotherapy; marked increase in
DTC numbers predicted significantly shorter PFS.Whether the
reevaluation of the DTC status after completion of therapy may
contribute to selection of patients who might benefit from ex-
tended or intensified treatment remains to be investigated.
Stem Cell Hypothesis
A provocative hypothesis has been introduced recently
with respect to natural history and progression of ovarian
cancer. While the ‘‘classical’’ stochastic model of cancer de-
velopment holds that any cell may become a source of malig-
nant transformation, emerging evidence supports the view that
only a minor subpopulation of cancer cells has the potential to
initiate cancer growth. These cells, called cancer stem cells
(CSCs), have the ability to self-renew, propagate tumorigenesis,
and are usually drug-resistant.19 Experimental studies on stem
cell biology have given new impetus to the cancer stem cell
theory. Cancer stem cells are assumed to play an important role
in the development of various tumor entities, such as breast and
gastrointestinal cancer, retinoblastoma, and ovarian cancer.20,21
Interestingly, ovarian cancer cell lines feature ‘‘side population’’
cells with potential to differentiate into cancers with different
histologies, suggesting the pluripotent character of stem cells.22
One currently debated hypothesis is the theory that DTC/
CTC, the surrogate marker for minimal residual disease and
possibly precursor of systemic metastasis, represent in fact
cancer stemcells.MostDTCs in breast cancer seem to express a
putativeCSCphenotype, such asALDH1positivityor presence
of CD44 and absence of CD24, whereas CTCs were reported
to exhibit stem cell and epithelial-mesenchymal transition
markers.23,24 Several characteristics of ovarian cancer (eg, high
recurrence rates and multidrug resistance) suggest that the dis-
easemight be initiated andmaintained by a unique population of
cells with stem cellYlike properties.21 Advanced ovarian cancer
generally responds to platinum-based combination therapy;
however, this initial regression is often followed by emergence of
therapy-resistant cell clones. One possible explanation for this
phenomenon is the CSC-induced drug-resistance: standard
therapies fail to target tumor-initiating cells.21
CONCLUSIONS
Despite advances in surgical and systemic therapy,
ovarian cancer leads to relapse in 60%ofpatientswithin 5 years,
resulting in poor OS. Currently, therapy efficacy is assessed
by physical examinations, imaging, and evaluation of CA125
levels. New biomarkers are thus necessary for better prediction
and prognostication.
Early hematogenous tumor cell dissemination is a com-
mon phenomenon observed in most solid tumors. Recent data
support the clinical relevance of these cells; in the present re-
port, we demonstrate significant impact of the presence of
DTCs in the BM on survival. Whether these patients might
benefit from extended ormore aggressive therapy remains to be
evaluated in future trials.
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